Abstract

The proposed Mayo Alzheimer's Disease Research Center (ADRC) will build upon the experience of the previously funded Mayo Alzheimer's Disease Center (P30) and the new faculty at Mayo Jacksonville, FL and the Mayo Scottsdale, AZ to address research questions in aging and Alzheimer's disease (AD). The ADRC will consist of five cores: Administrative Core, Clinical and Research Support Core, Neuropathology and Genetics Core, Neuroimaging Core and Education and Information Transfer Core, and two projects: Project 1: """"""""Cytoskeletal Pathology in the Neurodegeneration of AD,""""""""Project """"""""The contribution of Leukoaraisosis to Cognitive Impairment in Aging and Alzheimer's Disease."""""""" The Center will address several scientific themes including neuroepidemiology of dementia and AD, the boundary between normal aging and AD, and predictors of cognitive impairment in asymptomatic persons. New faculty appointments in Mayo Jacksonville in the basic science of amyloid processing, tau, genetics and antibody development will complement the clinical and epidemiology expertise in the remainder of the Center. Investigators in Scottsdale will add functional imaging studies in at-risk subjects to pursue the scientific themes of the Center. The proposed ADRC will extend the productivity of the existing Alzheimer's Disease Center and develop new insights into aging and AD.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
3P50AG016574-03S1
Application #
6478218
Study Section
Special Emphasis Panel (ZAG1 (J5))
Program Officer
Phelps, Creighton H
Project Start
1999-05-01
Project End
2004-04-30
Budget Start
2001-08-01
Budget End
2002-04-30
Support Year
3
Fiscal Year
2001
Total Cost
$123,176
Indirect Cost

  Institution

Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905

  Publications

Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Sahoo, Aradhana; Bejanin, Alexandre; Murray, Melissa E et al. (2018) TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia. J Alzheimers Dis 64:1227-1233
Kang, Silvia S; Ebbert, Mark T W; Baker, Kelsey E et al. (2018) Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J Exp Med 215:2235-2245
Pakhomov, Serguei V S; Eberly, Lynn E; Knopman, David S (2018) Recurrent perseverations on semantic verbal fluency tasks as an early marker of cognitive impairment. J Clin Exp Neuropsychol 40:832-840
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Sakae, Nobutaka; Bieniek, Kevin F; Zhang, Yong-Jie et al. (2018) Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol Commun 6:63
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872

Showing the most recent 10 out of 1014 publications